Technology | Stents Bare Metal | December 14, 2017

FDA Approves New Indication for NuMed CP Stent System

Covered stent may now be used to patch blood vessel tears during transcatheter valve replacements

FDA Approves New Indication for NuMed CP Stent System

December 14, 2017 — The U.S. Food and Drug Administration (FDA) announced clearance for NuMed’s Cheatham Platinum (CP) Stent System, which includes the Covered CP Stent and the Covered Mounted CP Stent. The Covered CP Stent is a metal framework covered with cloth to patch a blood vessel tear in patients born with heart defects. The device was approved previously to reopen a blocked or narrowed aorta.

The stents are compressed and placed using a balloon-in-balloon (BiB) catheter. The catheter is inserted through the skin in the upper leg (groin) and pushed through the blood vessels until it reaches the target location. The stent is then expanded with the balloon. Once the stent is in place, the balloon catheter is removed from the body.

Patients born with heart defects often receive a pulmonary valve conduit (a tube with a valve inside), also known as a right ventricular outflow tract (RVOT) conduit. The RVOT conduit is used to correct the defects. Over time, the conduit may become narrowed or leaky and will need to be replaced. If a patient who has previously had a conduit implanted needs a new pulmonic valve, one option for replacement is the use of a transcatheter heart valve (THV). As part of the procedure to replace the pulmonic valve a BiB catheter is used to widen the area where the new valve will be located. Sometimes, this process causes the RVOT conduit to rupture or tear. The Covered CP Stent is used to cover the tear in the conduit before implanting a THV.

If the Covered CP stent is able to successfully close the tear in the RVOT conduit, the surgeon may be able to continue implanting the new THV. If this approach is possible, the new valve can be implanted without open-heart surgery. In a clinical study of 50 patients, about 9 out of 10 had successful closure of the conduit tear with use of the Covered CP Stent followed by successful implantation of a pulmonic valve.

  • The Covered CP Stents should not be used in patients who:
  • Are too small to allow safe delivery of the stent without injury to a systemic vein or to the right side of the heart;
  • Exhibit clinical or biological signs of infection;
  • Have active infection in the heart (endocarditis); and/or
  • Are pregnant.

For more information: www.numedinc.com

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init